Ignite Creation Date:
2024-05-06 @ 12:47 AM
Last Modification Date:
2024-10-26 @ 10:54 AM
Study NCT ID:
NCT01653444
Status:
COMPLETED
Last Update Posted:
2016-06-24
First Post:
2012-07-24
Brief Title:
Evaluate the Safety and Exploratory Efficacy of GC1119
Sponsor:
Green Cross Corporation
Organization:
GC Biopharma Corp
Study Overview
Official Title:
Multicenter and Dose Escalation Phase 1 Study to Evaluate the Safety and Exploratory Efficacy of GC1119Recombinant Human α-galactosidase A for Enzyme Replacement Therapy in Fabry Disease Patients
Status:
COMPLETED
Status Verified Date:
2016-06
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose of this study is to evaluate the safety and exploratory efficacy of GC1119 recombinant human α-galactosidase A for enzyme replacement therapy in Fabry disease patients
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None